Current Research Studies

Cancer – ACNS1422: Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients


Condition or Therapy:

WNT-driven medulloblastoma


Cancer and Blood Disorders

Study Number: ACNS1422

What is the goal of this study?

This phase 2 trial studies how well reduced doses of radiation therapy to the brain and spine (craniospinal) and chemotherapy work in treating patients with newly diagnosed type of brain tumor called wingless (WNT)-driven medulloblastoma.

Who can join the study?

This study might be a good fit for children and young adults who:

  • Between the ages of 3 and 21
  • Newly diagnosed with medulloblastoma in the WNT subgroup

Researchers use many other factors to decide whether a patient can take part in a study (inclusion criteria) or cannot take part (exclusion criteria). The study team at Seattle Children’s can explain what these factors mean for you or your child.

What will happen if my child takes part in this study?

You can read more about this study on

Who can I contact for more information?

To learn more, call 206-987-2106 or send us an email.

Study Location(s):

Seattle Children’s Hospital campus

Principal Investigator:

Dr. Sarah Leary